Bristol Myers Squibb disclosed that a patient died after receiving investigational autoimmune CAR-T therapy in an early Phase 1 setting for multiple sclerosis, according to a report in STAT+. The patient developed motor symptoms that did not resolve with standard autoimmune treatment, then received a potent immunosuppressant before septic pneumonia and death. The disclosure lands amid heightened attention to CAR-T autoimmune trial safety, after earlier disclosures of inflammatory events and pauses across the same platform class. For CAR-T developers and trial sponsors, the update reinforces the clinical risk-management problem of separating disease-activity flares from treatment-related toxicity and tailoring immune suppression and infection monitoring protocols. What to watch: next safety reporting and protocol modifications that address infection risk and inflammatory sequelae after dose escalation.